RMEI: Recent Episodes

ReachMD

Guest: David P. Hudesman, MD

It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.

Guest: Anita Afzali MD, MPH, FACG, AGAF

The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.

Guest: Peter A. Lio, MD

Guest: Mark Boguniewicz, MD

Guest: Eric Simpson, MD, MCR

Please note: This activity is no longer available for continuing education credit.

Tune in as a multidisciplinary panel discusses a clinician's question about the appropriateness of combining two biologics in a very young child with several atopic diseases.

Guest: Peter A. Lio, MD

Guest: Mark Boguniewicz, MD

Guest: Eric Simpson, MD, MCR

Please note: This activity is no longer available for continuing education credit.

A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis. Her dermatologist wants to take the next step and start her on a biologic, but she's worried about the patient's occular history and dupilumab's conjunctivitis risk. Find out what the experts have to say about this doctor's dilemma.

Guest: Peter A. Lio, MD

Guest: Mark Boguniewicz, MD

Guest: Eric Simpson, MD, MCR

Please note: This activity is no longer available for continuing education credit.

Infants have the highest incidence of atopic dermatitis in the US but the fewest treatment options. This is a case a doctor submitted about a baby who is refractory to multiple oral and topical treatments. A multidisciplinary panel discusses how they would approach the baby's treatment, emerging options for this vulnerable patient population, and if anything can be done now to prevent progression of the atopic march later.

Host: Anne O'Donnell, MD

Guest: Patrick Flume, MD

Please note: This activity is no longer available for continuing education credit.

Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review two patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.

Host: Joseph K. Han, MD

Please note: This activity is no longer available for continuing education credit.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

Host: Anne O'Donnell, MD

Guest: Robert "Brinkley" Sewell

Please note: This activity is no longer available for continuing education credit.

The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.

Host: Reynold A. Panettieri, Jr., MD

Guest: Michael Wechsler, MD

Guest: Jonathan Corren, MD

Please note: This activity is no longer available for continuing education credit.

The management of severe asthma has changed drastically after the introduction of biologics. However, their introduction comes with many questions, such as, When should they be used and in whom? This Care Team ForumSM brings pulmonologists and an allergist/immunologist in dialogue with a patient about the immunologic underpinning of asthma pathology and how it relates to identifying patients appropriate for step-up care with biologics.

Host: Peter A. Lio, MD

Guest: Eric Simpson, MD, MCR

Guest: Mark Boguniewicz, MD

Please note: This activity is no longer available for continuing education credit.

“I begged my doctor for something else – there had to be something else,” Pam.

For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like.

Host: Leora Horn, MD, MSc

Please note: This activity is no longer available for continuing education credit.

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

Host: Chrysalyne D. Schmults, MD, MSCE (Chair)

Guest: Omid Hamid, MD

Guest: Anokhi Jambusaria, MD, MSCE, FAAD

Please note: This activity is no longer available for continuing education credit.

Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.

Host: Patricia K. Coyle, MD

Guest: Clyde E. Markowitz, MD

Please note: This activity is no longer available for continuing education credit.

Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSMactivity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.

Host: Chrysalyne D. Schmults, MD, MSCE (Chair)

Guest: Omid Hamid, MD

Guest: Anokhi Jambusaria, MD, MSCE, FAAD

Please note: This activity is no longer available for continuing education credit.

The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.